They tested LincRNA-p21 expression in urine samples from 30 prostate cancer patients and 49 BPH patients, found that lincRNA-p21 was significantly higher in the urine of prostate cancer patients, and further compared the ROC curve used by LincRNA-p21 and its combined with the common serum marker PSA, and found that the specificity increased significantly after testing lincRNA-p21 and PSA together, but the sensitivity was not significantly changed. Here, KLK3 is linked to prostate carcinoma.